Biophan Announces Issuance of Two New Patents in MRI Compatibility Expands Lead in Intellectual Property

Applications include the use of leads for implantable devices and for
interventional medical procedures.
Mr.
"We are pleased to now be making progress with multiple companies
on both exclusive and non-exclusive arrangements across a wide arena
of biomedical devices that have the potential to make a significant
improvement in the ability of physicians to care for their patients ,"
said Mr. The
forward-looking statements contained herein are made only as of the
date of this press release, and Biophan undertakes no obligation to
publicly update such forward-looking statements to reflect subsequent
events or circumstances. Studies will be
conducted in an HIV immunization model through IAVI's affiliated network of
scientific investigators and laboratories .iavi.

sensitively solubility

S.biophan.
When combined with disease-specific antigens, the technology creates
JuvaVax (TM) vaccines capable of activating substantial antibody- and
cell-mediated immune responses, particularly induction of cytotoxic T
lymphocytes.6200
mdcleary@juvaris.

insensitive biosensors

HAYWARD, Calif. The Company develops enabling
technologies for implanted medical systems such as pacemakers and
interventional surgical devices such as catheters, guidewires, stents,
and other implants to allow them to be safely and effectively imaged
under MRI. The JuvImmune(TM) product has
been shown to be at least 50 -times more potent at triggering innate immune
activation and interferon release than current immune stimulants.

This site is devoted to Biomedical Engineering, either in the electrical and mechanical engineering field.

nodule morphogenesis

patent; nanomagnetic particle thin-film coatings,
in which today's issued patent adds to our already broad coverage and
specifically teaches how to shield conductors such as pacemaker leads
and guidewires; and photonics, where we've developed extensive
fiber-optic solutions and patent coverage useful in addressing
problems of MRI imaging and safety.

Juvaris Announces Collaboration With the International AIDS Vaccine Initiative (IAVI)

Sloan and
Starr foundations; the governments of Canada, Denmark, Ireland, the
Netherlands, Norway, Sweden, the United Kingdom and the United States;
multilateral organizations including the European Union and the World Bank;
corporations such as BD (Becton, Dickinson + Co.

telecare sensitively

com.S.4 million (~1 million, US) are currently living with the infection ."

About Juvaris:
Juvaris BioTherapeutics was created in 2002 to develop an
immunotherapeutic product platform for the treatment of infectious diseases
and cancer using lipid-DNA complexes.

telecare motus

, Cholestech Corporation
(Nasdaq: CTEC) today announced that it has been granted a patent by the U . For more information
about Cholestech and its products visit us on the web at http://www. Committed to growth through innovation and developmental
leadership, Biophan and its licensors now hold a total of 104 U.
patents, licenses, or applications.

About IAVI:
IAVI (http://www.

sift swri

Cholestech LDX(R) is a registered trademark and Cholestech GDX(TM) is a
trademark of Cholestech Corporation.

(OTC BB: BIPH), a developer of
next-generation biomedical technology, has announced the issuance of
two new patents by the U.), Continental Airlines and
DHL; leading AIDS charities such as Crusaid, Deutsche AIDS Stiftung, and the
Until There's A Cure Foundation; and other private donors such as the Phoebe
W.399.

biomaterials motus

Y.
"The new patents will help ensure Biophan's leadership position
and competitive advantages in improving over $12 billion of medical
devices which ship every year with limitations in working with MRI,"
said Mr. Patent and Trademark Office. 6,693,086 titled "Systemic Immune Activation Method
Using Nucleic Acid-Lipid Complexes" providing broad intellectual property
coverage for the JuvImmune(TM) technology.

veryan visuo

----

New Patents Strengthen Company 's Competitive Advantage in Several
Multi-Billion-Dollar Healthcare Markets

Biophan Technologies, Inc. Weiner."
The devices covered by Biophan's intellectual property portfolio
cover not only today's products, but also key components of future
medical devices.

swri sift

Safe Harbor Statement of Cholestech Corporation Under the Private
Securities Litigation Reform Act of 1995:
This release contains forward-looking statements as defined in the Private
Securities Litigation Reform Act of 1995, including statements regarding the
approach of the new patent as compared to other patents for the measurement of
HDL and the development of the LDX Lipid/ALT cassette. Currently , millions of patients with
implanted medical devices, such as pacemakers, cannot be safely or
effectively imaged with MRI technology, and those with stents have to
undergo invasive diagnostic procedures due to image problems with MRI
and X-ray that have previously limited the ability to see the inside
of a stent. Weiner added: "While Biophan previously discontinued work on a
photonic pacemaker lead when our other development efforts solved the
problems in a much simpler and more cost-effective manner, we believe
that a range of future implantable and surgical medical devices will
use photonic solutions, and we are pleased to have a large and growing
patent portfolio covering this emerging capability.
Clearly, in the areas of making devices safe and visible under MRI, we
have covered the waterfront. The technology is also being used to create MRI contrast
agents, and has expanded to include other applications, such as drug
delivery and power systems derived from body heat.

veryan motus

The
Company believes that this patent provides a very different approach than
those of other existing patents describing the measurement of HDL and that
this patent also permits the development of the Cholestech LDX Lipid
Profile/Alanine Aminotransferase ("Lipid/ALT") cassette by preventing the
interference of the HDL chemistry with the ALT assay on the same cassette. Weiner.
The research collaboration will consist of testing the JuvImmune(TM) /
JuvaVax(TM) Immunostimulant combined with HIV antigens . Juvaris was
recently issued Patent No.com

sift linolenic

All other trademarks mentioned in this
document are the property of their respective owners. "The issuance of
these Biophan patents and others, such as the anti-antenna patent, and
nanoparticle coatings, has been very helpful in moving negotiations
into the final contract phase," said Mr. Such next-generation products include diagnostic
implants , such as smart stents and other implantable devices where the
device and electrical circuitry are both safe and visible with MRI,
and are also capable of communicating telemetry to physicians without
interference.S.
patents, 8 recently-allowed applications that will issue as patents in
the near future, and 68 pending applications at various stages of
examination at the U. Biophan has
joint development arrangements with Boston Scientific (NYSE: BSX) and
NASA's Ames Center for Nanotechnology .
The need for a vaccine to prevent HIV infection and AIDS worldwide is
urgent. Cationic lipids are formulated with
non-coding DNA (plasmid) to create JuvImmune(TM), a single lipid-DNA complex ,
which as an immunostimulation product will have utility in a number of
non-antigen immunotherapeutic applications.

Submit your site too!!!

t3i sift

Patent and Trademark Office that extend
the Company's competitive edge in the marketplace for the rapidly
emerging field of MRI safety and image compatibility for medical
instruments and implanted devices.S. This total includes 28 issued U.
Approximately 4 . Immunological responses elicited by the lipid-DNA complexes have
been successfully demonstrated in both prophylactic and therapeutic settings
in a variety of mammals including rodents, rabbits , cats, dogs and non-human
primates.

biomaterials orthoses

cholestech. "There is a certain
degree of uncertainty with patents that are pending and a strong
degree of strength when patents actually issue with strong claims.org) is a global not-for-profit organization working to
accelerate the development of a vaccine to prevent HIV infection and AIDS. Haas Charitable Trust B.

biomaterials biomedical

Patent Office (6,881,581) and the European Patent Office (EP 1,329,724) for a
new method of measuring High Density Lipoprotein ("HDL") in human blood. Cholestech offers efficient and economic diagnostic testing for
cholesterol and related lipids , blood glucose and glycemic control, and liver
function at the point of care.

Business Editors /Biotech Writers
BIOWIRE2K

ROCHESTER, N."
The newly issued patents have also furthered Biophan 's progress
toward finalizing agreements with product development and
manufacturing partners in the healthcare industry. Similarly, when it comes to making stents
visible under MRI, we clearly have both the demonstrated capability
and the intellectual property coverage.,
a private biotechnology company, today announced a research collaboration with
the International AIDS Vaccine Initiative (IAVI) to use Juvaris'
immunostimulant technology in the screening of Human Immunodeficiency Virus
(HIV) vaccine candidates.1 million AIDS-related
deaths occurred in 2004.
In commenting on the IAVI collaboration, Juvaris' Co-founder, Chairman and
CEO Martin D.com.

biomaterials nodule

Additional considerations and
important risk factors are described in Cholestech's Annual Report on Form 10-
K, Quarterly Reports on Form 10-Q and other filings with the Securities and
Exchange Commission. Weiner. They also cover the use of external
leads used to receive and relay information through the MRI
environment , such as surface-mounted ECG electrode data.com

Cautionary Statement Regarding Forward-Looking Statements

Certain statements included in this press release may constitute
forward-looking statements. Actual results could differ materially
from such statements expressed or implied herein as a result of a
variety of factors including, but not limited to: the development of
Biophan 's MRI technologies; the approval of Biophan's patent
applications; the successful implementation of Biophan's research and
development programs; the acceptance by the market of Biophan's
products; competition and the timing of projects and trends in future
operating performance, as well as other factors expressed from time to
time in Biophan's periodic filings with the Securities and Exchange
Commission (the "SEC"). PLEASANTON, Calif. Cleary stated "Juvaris is excited to collaborate with IAVI in
the screening of HIV vaccine candidates using the Company's Immunostimulant/
Vaccine technology platform. Our preclinical
testing has demonstrated potent cellular and antibody-mediated immune
stimulation as well as the efficacy of oral administration. The DNA in these complexes does
not code for protein, but rather, through a combined synergistic effect with
lipids, strongly stimulates immune responses. IAVI's financial and in-kind
supporters include the Bill + Melinda Gates, Rockefeller , Alfred P.

telemonitoring lymphocyte

S. Health care providers can use the CLIA-waived
Cholestech LDX(R) and GDX(TM) Systems to initiate and monitor the progress of
patient therapy. We believe the various attributes of the Juvaris
vaccine platform strongly support IAVI's vaccine efforts.

Company Contact:
Martin D.

telecare lymphocyte

About Cholestech
Cholestech is committed to enabling people to lead longer, healthier and
more active lives. Four Biophan
technologies include advances in nanotechnology and thin-film
coatings. Biophan's goal is to make all
biomedical devices capable of safely and successfully working with
MRI, and delivering other technologies which will improve quality of
life . IAVI's mission is to ensure the
development of a safe, effective and accessible vaccine to prevent HIV
infection and AIDS.
Over the past nine months, the Company has announced collaborations or
investigational studies with Cell Genesys, SomaGenics, the University of
California-San Francisco , Penn State University, the Defense Advanced Research
Projects Agency (DARPA), the National Institutes of Health (NIH) and the
Institute for Antiviral Research at Utah State University, and now the
International AIDS Vaccine Initiate (IAVI).
Founded in 1996 and operational in 23 countries, IAVI and its network of
collaborators research and develop vaccine candidates.

biomaterials staphylococcus

By providing effective disease management solutions,
Cholestech's goal is to be a leading provider of diagnostic tools and
information for immediate risk assessment and therapeutic monitoring of heart
disease and diabetes."

About Biophan Technologies

Biophan develops and markets cutting-edge technologies designed to
make biomedical devices safe and compatible with the magnetic
resonance imaging (MRI) environment. This system provides the opportunity to develop many
disease-specific vaccine products, for which there are significant unmet
medical needs.
The Company encourages investment and partnering inquiries and can be
reached at its website @ http://www.

t3i orthoses

Actual results may
differ materially from those in the forward-looking statements due to risks
and uncertainties, including: risks related to proprietary technology; the
outcome of ongoing research and development efforts; risks inherent in the
regulatory approval process and other factors.
The second newly-issued patent relates to the creation of medical
leads or wires that are based upon fiber-optic components.
925.

neurotherapy nian

Michael Weiner, CEO of Biophan ,
made the announcement. For more information, please visit www., Juvaris BioTherapeutics Inc. IAVI also advocates
for a vaccine to be a global priority and works to assure that a future
vaccine will be accessible to all who need it.

nian morphogenesis

Cholestech provides easy to use, accessible diagnostic
tools and information to health care practitioners in over 35 countries around
the world. "Biophan has already gained important patent and
technological command of the three fundamental approaches to MRI
compatibility: anti-antenna designs, which is the subject of a
recently issued U. "This was our founding mission, and we are pleased to
be demonstrating this continued progress. As a result , this press release should be read
in conjunction with Biophan's periodic filings with the SEC.9 million new HIV infections and 3.

t3i solubility

S. Moreover, substantial immune responses have been induced following
oral administration.juvaris. Cleary
Juvaris BioTherapeutics, Inc.

orthoses biomaterials

These newly-issued patents build on the base Biophan has already
established with the development of proprietary solutions that make
medical devices safe and compatible with the magnetic resonance
imaging (MRI) environment . The patents
describe methods that make such systems safe and image compatible,
with virtually zero interference with MRI images. Statistics from the World Health Organization-UNAIDS joint program on
the epidemic estimated in December 2004 that worldwide, more than 60 million
adults and children have been infected with HIV; 28 million have died of AIDS,
and 39. Juvaris
appreciates the opportunity to demonstrate the power of its immunostimulation
technology through the IAVI collaboration.

sensitively staphylococcus

Cholestech Announces the Issuance of U.S. and European Patents for New HDL Test

"
One of the newly-issued patents, issued to Biophan technology
partner, Nanoset LLC, provides fundamental patent protection for a
range of very important nano-particulate thin-film coating
characteristics that enable them to provide the electro-magnetic
shielding to make medical devices safe and image compatible under MRI
environments. The patents cover
areas including nanotechnology (nanomagnetic particle coatings ), radio
frequency filters, polymer composites, thermoelectric materials for
batteries generating power from body heat, and photonics. Life expectancy has been severely impacted by AIDS
in sub-Saharan African countries, and is now beginning to impact India, China,
Russia, and Eastern Europe.